Enovis Corp
NYSE:ENOV

Watchlist Manager
Enovis Corp Logo
Enovis Corp
NYSE:ENOV
Watchlist
Price: 22.49 USD -3.89% Market Closed
Market Cap: $1.3B

P/B

0.9
Current
2%
More Expensive
vs 3-y average of 0.8

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.9
=
Market Cap
$1.3B
/
Total Equity
$1.5B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.9
=
Market Cap
$1.3B
/
Total Equity
$1.5B

Valuation Scenarios

Enovis Corp is trading above its 3-year average

If P/B returns to its 3-Year Average (0.8), the stock would be worth $22.04 (2% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-2%
Maximum Upside
+262%
Average Upside
112%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 0.9 $22.49
0%
3-Year Average 0.8 $22.04
-2%
5-Year Average 0.8 $22.05
-2%
Industry Average 3.1 $81.31
+262%
Country Average 2.5 $65.47
+191%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
US
Enovis Corp
NYSE:ENOV
1.3B USD 0.9 -1.1
US
Intuitive Surgical Inc
NASDAQ:ISRG
161.2B USD 9 56.4
US
Abbott Laboratories
NYSE:ABT
158.6B USD 3 25.3
US
Stryker Corp
NYSE:SYK
120.5B USD 5.4 37.1
IE
Medtronic PLC
NYSE:MDT
101.9B USD 2.1 22.1
US
Boston Scientific Corp
NYSE:BSX
84.8B USD 3.5 23.8
US
Edwards Lifesciences Corp
NYSE:EW
47.2B USD 4.6 43
US
IDEXX Laboratories Inc
NASDAQ:IDXX
44.1B USD 27.5 41.7
DE
Siemens Healthineers AG
XETRA:SHL
38.3B EUR 2.1 18.1
US
Becton Dickinson and Co
NYSE:BDX
41.4B USD 1.6 23.5
US
Resmed Inc
NYSE:RMD
30.9B USD 4.9 20.8

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 10 946 companies
10th percentile
0.9
Low
0 — 1.5
Typical Range
1.5 — 4.8
High
4.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.5
Median 2.5
70th Percentile 4.8
Max 147 580.5

Enovis Corp
Glance View

Enovis Corp., a company with a steadfast commitment to innovation and growth, operates within the specialized world of medical technology. Originally a part of Colfax Corporation, it underwent a strategic transformation, branching out into its own entity, laser-focused on advancing human mobility through cutting-edge orthopedic solutions. Enovis has carved its niche by developing and manufacturing high-quality, bespoke orthopedic products that serve both surgical and non-surgical needs. These offerings are designed to enhance patient recovery and mobility, thereby improving quality of life. Its extensive product portfolio includes surgical implants, bracing, rehabilitation solutions, and intelligent digital care platforms, positioning Enovis at the intersection of healthcare and technology. Revenue for Enovis streams from its diverse array of products and solutions targeted at healthcare professionals and institutions worldwide. The company thrives by engaging in both direct sales and a network of distributors to ensure its innovative solutions reach a broad spectrum of the healthcare landscape. By continually investing in research and development, Enovis maintains its competitive edge, launching new products that address evolving medical needs. This proactive approach not only caters to the existing demand but also stimulates new markets by educating and training medical professionals and leading them through transformative, evidence-based clinical outcomes. In essence, Enovis Corp. excels by integrating science and technology to fuel both financial growth and human betterment.

ENOV Intrinsic Value
56.33 USD
Undervaluation 60%
Intrinsic Value
Price $22.49
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett